AIxCrypto Holdings, Inc.
AIxCrypto Holdings, Inc. (AIXC) Stock Competitors & Peer Comparison
See (AIXC) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AIXC | $1.22 | -1.61% | 6.4M | 0.44 | $2.85 | N/A |
| ONC | $365.81 | +3.20% | 38.7B | 724.28 | $0.50 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | N/A |
| DFTX | $16.80 | -2.75% | 1.7B | N/A | N/A | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LFMDP | $22.68 | -0.09% | 998.4M | -10.06 | -$2.26 | N/A |
| CGEM | $14.12 | +1.73% | 806.4M | -4.11 | -$3.32 | N/A |
| ATAI | $3.86 | +0.95% | 731.9M | -4.67 | -$0.83 | N/A |
| HITI | $2.50 | +3.96% | 218.7M | -5.41 | -$0.46 | N/A |
Stock Comparison
AIXC vs ONC Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, ONC has a market cap of 38.7B. Regarding current trading prices, AIXC is priced at $1.22, while ONC trades at $365.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas ONC's P/E ratio is 724.28. In terms of profitability, AIXC's ROE is -0.73%, compared to ONC's ROE of +0.02%. Regarding short-term risk, AIXC is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check ONC's competition here
AIXC vs WBA Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, AIXC is priced at $1.22, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas WBA's P/E ratio is -1.64. In terms of profitability, AIXC's ROE is -0.73%, compared to WBA's ROE of -0.70%. Regarding short-term risk, AIXC is more volatile compared to WBA. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check WBA's competition here
AIXC vs DFTX Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, DFTX has a market cap of 1.7B. Regarding current trading prices, AIXC is priced at $1.22, while DFTX trades at $16.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas DFTX's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.73%, compared to DFTX's ROE of -0.86%. Regarding short-term risk, AIXC is more volatile compared to DFTX. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check DFTX's competition here
AIXC vs HROWL Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, AIXC is priced at $1.22, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas HROWL's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.73%, compared to HROWL's ROE of -0.09%. Regarding short-term risk, AIXC is more volatile compared to HROWL. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check HROWL's competition here
AIXC vs HROWM Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, AIXC is priced at $1.22, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas HROWM's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.73%, compared to HROWM's ROE of -0.09%. Regarding short-term risk, AIXC is more volatile compared to HROWM. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check HROWM's competition here
AIXC vs LFMDP Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, LFMDP has a market cap of 998.4M. Regarding current trading prices, AIXC is priced at $1.22, while LFMDP trades at $22.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas LFMDP's P/E ratio is -10.06. In terms of profitability, AIXC's ROE is -0.73%, compared to LFMDP's ROE of +2.22%. Regarding short-term risk, AIXC is more volatile compared to LFMDP. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check LFMDP's competition here
AIXC vs CGEM Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, CGEM has a market cap of 806.4M. Regarding current trading prices, AIXC is priced at $1.22, while CGEM trades at $14.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas CGEM's P/E ratio is -4.11. In terms of profitability, AIXC's ROE is -0.73%, compared to CGEM's ROE of -0.42%. Regarding short-term risk, AIXC is more volatile compared to CGEM. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check CGEM's competition here
AIXC vs ATAI Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, ATAI has a market cap of 731.9M. Regarding current trading prices, AIXC is priced at $1.22, while ATAI trades at $3.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas ATAI's P/E ratio is -4.67. In terms of profitability, AIXC's ROE is -0.73%, compared to ATAI's ROE of -1.08%. Regarding short-term risk, AIXC is more volatile compared to ATAI. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check ATAI's competition here
AIXC vs HITI Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, HITI has a market cap of 218.7M. Regarding current trading prices, AIXC is priced at $1.22, while HITI trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas HITI's P/E ratio is -5.41. In terms of profitability, AIXC's ROE is -0.73%, compared to HITI's ROE of -0.40%. Regarding short-term risk, AIXC is more volatile compared to HITI. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check HITI's competition here
AIXC vs LFMD Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, LFMD has a market cap of 135.7M. Regarding current trading prices, AIXC is priced at $1.22, while LFMD trades at $2.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas LFMD's P/E ratio is -11.28. In terms of profitability, AIXC's ROE is -0.73%, compared to LFMD's ROE of +2.22%. Regarding short-term risk, AIXC is more volatile compared to LFMD. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check LFMD's competition here
AIXC vs LFLY Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, LFLY has a market cap of 114.9M. Regarding current trading prices, AIXC is priced at $1.22, while LFLY trades at $37.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas LFLY's P/E ratio is -0.04. In terms of profitability, AIXC's ROE is -0.73%, compared to LFLY's ROE of +0.25%. Regarding short-term risk, AIXC is less volatile compared to LFLY. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check LFLY's competition here
AIXC vs YI Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, YI has a market cap of 70.9M. Regarding current trading prices, AIXC is priced at $1.22, while YI trades at $8.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas YI's P/E ratio is -2.82. In terms of profitability, AIXC's ROE is -0.73%, compared to YI's ROE of +0.11%. Regarding short-term risk, AIXC is more volatile compared to YI. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check YI's competition here
AIXC vs PETS Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, PETS has a market cap of 63.1M. Regarding current trading prices, AIXC is priced at $1.22, while PETS trades at $2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas PETS's P/E ratio is -0.95. In terms of profitability, AIXC's ROE is -0.73%, compared to PETS's ROE of -1.22%. Regarding short-term risk, AIXC is more volatile compared to PETS. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check PETS's competition here
AIXC vs RAD Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, AIXC is priced at $1.22, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas RAD's P/E ratio is -0.05. In terms of profitability, AIXC's ROE is -0.73%, compared to RAD's ROE of +2.76%. Regarding short-term risk, AIXC is less volatile compared to RAD. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check RAD's competition here
AIXC vs KYNB Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, KYNB has a market cap of 33.7M. Regarding current trading prices, AIXC is priced at $1.22, while KYNB trades at $8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas KYNB's P/E ratio is -0.65. In terms of profitability, AIXC's ROE is -0.73%, compared to KYNB's ROE of -1.26%. Regarding short-term risk, AIXC is more volatile compared to KYNB. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check KYNB's competition here
AIXC vs RNTX Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, RNTX has a market cap of 31.8M. Regarding current trading prices, AIXC is priced at $1.22, while RNTX trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas RNTX's P/E ratio is -0.41. In terms of profitability, AIXC's ROE is -0.73%, compared to RNTX's ROE of -2.17%. Regarding short-term risk, AIXC is more volatile compared to RNTX. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check RNTX's competition here
AIXC vs POM Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, POM has a market cap of 23.7M. Regarding current trading prices, AIXC is priced at $1.22, while POM trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas POM's P/E ratio is -4.43. In terms of profitability, AIXC's ROE is -0.73%, compared to POM's ROE of +0.07%. Regarding short-term risk, AIXC is less volatile compared to POM. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check POM's competition here
AIXC vs MSLE Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, MSLE has a market cap of 14.5M. Regarding current trading prices, AIXC is priced at $1.22, while MSLE trades at $11.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas MSLE's P/E ratio is 4.37. In terms of profitability, AIXC's ROE is -0.73%, compared to MSLE's ROE of N/A. Regarding short-term risk, AIXC is more volatile compared to MSLE. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check MSLE's competition here
AIXC vs MEDS Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, MEDS has a market cap of 13.3M. Regarding current trading prices, AIXC is priced at $1.22, while MEDS trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas MEDS's P/E ratio is -0.31. In terms of profitability, AIXC's ROE is -0.73%, compared to MEDS's ROE of -0.26%. Regarding short-term risk, AIXC is more volatile compared to MEDS. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check MEDS's competition here
AIXC vs CJJD Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, AIXC is priced at $1.22, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas CJJD's P/E ratio is -0.46. In terms of profitability, AIXC's ROE is -0.73%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, AIXC is more volatile compared to CJJD. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check CJJD's competition here
AIXC vs NEUP Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, NEUP has a market cap of 8.2M. Regarding current trading prices, AIXC is priced at $1.22, while NEUP trades at $4.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas NEUP's P/E ratio is -1.08. In terms of profitability, AIXC's ROE is -0.73%, compared to NEUP's ROE of -0.08%. Regarding short-term risk, AIXC is more volatile compared to NEUP. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check NEUP's competition here
AIXC vs SSY Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, AIXC is priced at $1.22, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas SSY's P/E ratio is -2.86. In terms of profitability, AIXC's ROE is -0.73%, compared to SSY's ROE of -0.18%. Regarding short-term risk, AIXC is less volatile compared to SSY. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check SSY's competition here
AIXC vs HKPD Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, HKPD has a market cap of 7.5M. Regarding current trading prices, AIXC is priced at $1.22, while HKPD trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas HKPD's P/E ratio is 4.00. In terms of profitability, AIXC's ROE is -0.73%, compared to HKPD's ROE of -0.01%. Regarding short-term risk, AIXC is more volatile compared to HKPD. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check HKPD's competition here
AIXC vs BGMSP Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, BGMSP has a market cap of 6M. Regarding current trading prices, AIXC is priced at $1.22, while BGMSP trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas BGMSP's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.73%, compared to BGMSP's ROE of -7.22%. Regarding short-term risk, AIXC is more volatile compared to BGMSP. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check BGMSP's competition here
AIXC vs MDVL Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, AIXC is priced at $1.22, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas MDVL's P/E ratio is -0.05. In terms of profitability, AIXC's ROE is -0.73%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, AIXC is less volatile compared to MDVL. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check MDVL's competition here
AIXC vs ATNFW Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, AIXC is priced at $1.22, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas ATNFW's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.73%, compared to ATNFW's ROE of -1.93%. Regarding short-term risk, AIXC is less volatile compared to ATNFW. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check ATNFW's competition here
AIXC vs NVOH Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, NVOH has a market cap of 2.3M. Regarding current trading prices, AIXC is priced at $1.22, while NVOH trades at $21.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas NVOH's P/E ratio is 13.37. In terms of profitability, AIXC's ROE is -0.73%, compared to NVOH's ROE of +0.00%. Regarding short-term risk, AIXC is less volatile compared to NVOH. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check NVOH's competition here
AIXC vs BGMS Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, BGMS has a market cap of 2M. Regarding current trading prices, AIXC is priced at $1.22, while BGMS trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas BGMS's P/E ratio is -0.07. In terms of profitability, AIXC's ROE is -0.73%, compared to BGMS's ROE of -1.87%. Regarding short-term risk, AIXC is more volatile compared to BGMS. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check BGMS's competition here
AIXC vs AZNH Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, AIXC is priced at $1.22, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas AZNH's P/E ratio is 38.35. In terms of profitability, AIXC's ROE is -0.73%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, AIXC is more volatile compared to AZNH. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check AZNH's competition here
AIXC vs LFLYW Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, AIXC is priced at $1.22, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas LFLYW's P/E ratio is -0.04. In terms of profitability, AIXC's ROE is -0.73%, compared to LFLYW's ROE of +0.25%. Regarding short-term risk, AIXC is more volatile compared to LFLYW. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check LFLYW's competition here
AIXC vs BIMI Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, BIMI has a market cap of 1.2K. Regarding current trading prices, AIXC is priced at $1.22, while BIMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas BIMI's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.73%, compared to BIMI's ROE of -2.94%. Regarding short-term risk, AIXC is more volatile compared to BIMI. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check BIMI's competition here
AIXC vs POZN Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, POZN has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.22, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas POZN's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.73%, compared to POZN's ROE of +0.61%. Regarding short-term risk, AIXC is more volatile compared to POZN. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check POZN's competition here
AIXC vs IPXL Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.22, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas IPXL's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.73%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, AIXC is more volatile compared to IPXL. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check IPXL's competition here
AIXC vs ESRX Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.22, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas ESRX's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.73%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, AIXC is more volatile compared to ESRX. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check ESRX's competition here
AIXC vs CPD Comparison February 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.4M. In comparison, CPD has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.22, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of 0.44, whereas CPD's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.73%, compared to CPD's ROE of N/A. Regarding short-term risk, AIXC is more volatile compared to CPD. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check CPD's competition here